

HEALTHCARE MONTHLY

JULY 2023

Our healthcare team architects market-defining outcomes for some of the most innovative medical device, life science and diagnostics, healthcare services and pharmaceutical companies in the world.

BioTech / Pharma Healthcare Services

Life Sciences / Diagnostics Medical Devices

HEADLINE TRANSACTIONS

TARGET

ACQUIROR

ACQUISITION SYNOPSIS





- Novartis AG (NYSE:NVS) has reached a definitive agreement to acquire Chinook Therapeutics, Inc. (NASDAQ:KDNY)
- Chinook is a clinical stage biopharmaceutical company developing precision medicines for kidney diseases
- Novartis, based in Switzerland, develops, manufactures and markets branded and generic prescription drugs, active pharmaceutical ingredients, biosimilars and ophthalmic products
- Total Consideration: \$3.5 billion
- Per share price represents a premium of ~67%







- · Novo Holdings A/S and Gurnet Point Capital LLC have reached a definitive agreement to acquire Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK)
- · Paratek develops and commercializes novel therapies for life-threatening diseases and other public health threats
- · Novo Holdings is a Denmark-based holding and investment company that manages the assets and wealth of the Novo Nordisk Foundation
- · Gurnet Point Capital is a private equity firm with \$1.5 billion AUM
- · Total Consideration: \$462 million
- Per share price represents a premium of ~41%







- · UnitedHealth Group Inc/s Optum unit (NYSE:UNH) has reached a definitive agreement to acquire Amedisys, Inc. (NASDAQ:AMED)
- Amedisys delivers personalized home health, hospice and high-acuity care services, specializing in palliative and post-acute care
- UnitedHealth is a diversified healthcare company whose Optum segment provides care delivery, care management, wellness and consumer engagement and health financial services
- Total Consideration: \$3.3 billion in cash
- Per share price represents a premium of ~11%
- In May 2023, Amedisys agreed to be acquired by Option Care Health; per share price represented a premium of ~26%
- In June 2023, UnitedHealth outbid Option Care's deal offering \$101 per share compared to Option Care's offer of \$97 per share

Surgical Instrumentation Platform



- Steris plc (NYSE:STE) has reached a definitive agreement to acquire the surgical instrumentation, laparoscopic instrumentation and sterilization container assets from Becton, Dickinson and Company ("BD") (NYSE:BDX)
- BD is a medical technology company whose divestiture will include V. Mueller™, Snowden-Pencer™ and Genesis™ branded products, which are providers of surgical instruments and sterilization containers to healthcare customers, in addition to three manufacturing facilities
- Steris is a global provider of products and services that support patient care with a focus on infection prevention
- Total Consideration: \$540 million




BioTech / Pharma






HEALTHCARE GROWTH & VALUATION TRENDS


Enterprise Value / LTM Revenue




Enterprise Value / LTM EBITDA



LTM Revenue Growth




LTM Gross and EBITDA Margins*



*EBITDA Margins shown as the gray line.

LTM Stock Price Index





SELECTED HEALTHCARE TRANSACTIONS


Target	Acquiror	BioTech / Pharma Transactions
Sigilon Therapeutics, Inc. (NASDAQ:SGTX)	Eli Lilly and Company (NYSE:LLY)	Sigilon Therapeutics develops functional cures for patients with acute and chronic diseases, such as diabetes and lysosomal diseases, by providing stable and durable levels of therapeutic molecules to patients Total Consideration: \$310 million Per share price represents a premium of ~280%
Surface Oncology, Inc. (NASDAQ:SURF)	Coherus BioSciences, Inc. (NASDAQ: CHRS)	Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment Total Consideration: \$65 million, consisting of \$40 million in stock and anticipated net cash of between \$20 and \$25 million
Proteovant Sciences, Inc.	SK Biopharmaceuticals Co., Ltd. (KOSE:A326030)	Proteovant discovers and develops novel targeted protein degraders to treat patients with life-altering diseases such as breast and prostate cancer Total Consideration: \$48 million
Target	Acquiror	Life Sci / Diagnostics Transactions
ProciseDX, Inc.	Biosynex SA (EPA:ALBIO)	ProciseDX is an in vitro diagnostics company that develops and commercializes a broad portfolio of point-of-care diagnostic tests for use in physician offices, retail clinics and urgent care
Lunaphore	Bio-Techne	Lunaphore Technologies is a life sciences company
Technologies SA	Corporation (NASDAQ:TECH)	that develops fully automated spatial biology solutions using precision microfluid technology capable of revealing biomarkers in tumors

Selected TM Capital Healthcare Experience









TM Capital's Healthcare Industry Contacts



James McLaren Managing Director jmclaren@tmcapital.com 212.809.1414



John Dean Principal jdean@tmcapital.com 404.995.6234



Michael Goldman Managing Director mgoldman@tmcapital.com



Managing Director, Sponsor Coverage shunter@tmcapital.com 404.995.6232



Paul Smolevitz
Managing Director

